- Home
- SKYE vs WNEB Comparison
SKYE vs WNEB Comparison
Compare SKYE & WNEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- WNEB
- Stock Information
- Founded
- SKYE 2012
- WNEB 1853
- Country
- SKYE United States
- WNEB United States
- Employees
- SKYE N/A
- WNEB N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- WNEB Savings Institutions
- Sector
- SKYE Health Care
- WNEB Finance
- Exchange
- SKYE Nasdaq
- WNEB Nasdaq
- Market Cap
- SKYE 172.9M
- WNEB 165.5M
- IPO Year
- SKYE N/A
- WNEB N/A
- Fundamental
- Price
- SKYE $6.05
- WNEB $8.90
- Analyst Decision
- SKYE Strong Buy
- WNEB Hold
- Analyst Count
- SKYE 5
- WNEB 4
- Target Price
- SKYE $18.40
- WNEB $8.50
- AVG Volume (30 Days)
- SKYE 159.4K
- WNEB 39.9K
- Earning Date
- SKYE 08-09-2024
- WNEB 10-22-2024
- Dividend Yield
- SKYE N/A
- WNEB 3.23%
- EPS Growth
- SKYE N/A
- WNEB N/A
- EPS
- SKYE N/A
- WNEB 0.63
- Revenue
- SKYE N/A
- WNEB $74,435,000.00
- Revenue This Year
- SKYE N/A
- WNEB N/A
- Revenue Next Year
- SKYE N/A
- WNEB $5.16
- P/E Ratio
- SKYE N/A
- WNEB $13.68
- Revenue Growth
- SKYE N/A
- WNEB N/A
- 52 Week Low
- SKYE $1.44
- WNEB $6.00
- 52 Week High
- SKYE $19.41
- WNEB $9.25
- Technical
- Relative Strength Index (RSI)
- SKYE 50.99
- WNEB 59.33
- Support Level
- SKYE $5.89
- WNEB $8.45
- Resistance Level
- SKYE $7.11
- WNEB $8.99
- Average True Range (ATR)
- SKYE 0.67
- WNEB 0.18
- MACD
- SKYE 0.05
- WNEB -0.05
- Stochastic Oscillator
- SKYE 23.33
- WNEB 37.04
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the Company's revenues, profits, and assets are derived by the Bank from banking products and services.